Please login to the form below
Combination therapies in oncology: The benefits of integrated insights
14 June 2018 11am EDT | 8am PDT | 4pm BST | 5pm CE
In association with Pharmaceutical Executive
Register now: https://bit.ly/2L80Tme
Most experts believe combination therapies to be the future of oncology treatment. But with a number of new compounds approved and hundreds more in development, it’s difficult for many to identify which combinations and in what sequence, will form future treatment paradigms. In addition, the rising costs of newer agents and increased cost pressure creates an environment ripe for payer management.
In this webinar, pharma market research experts Anthony Greenwood, Dr Chris Gaj and Brett Gardiner will look at the challenges and opportunities for effectively launching combination therapies across tumor types and, referencing their experience in oncology, demonstrate how integrated insights from payers, KOLs, community oncologists and patients can help support bio-pharma companies with oncology assets in all stages of clinical development.
Key Learning Objectives:
Delegates will:
- Learn about the major themes, challenges and opportunities for marketing an oncology therapy in combination, including clinical trial design, pricing, sequencing and product attributes, amongst others
- Understand implications of combining therapies from more than one manufacturer, anticipated pricing challenges and considerations for indication expansion
- Understand the payer environment in oncology across the US and EU and uncover what evidence payers are looking for to make decisions about combination therapies
- Understand how KOLs see oncology market evolving and how combination therapies will be utilized
- Understand what effect patient characteristics may have on eventual treatment choice
- Learn how integrated insights across all stakeholder groups can benefit launch strategies
Company Details
Research Partnership
+44 (0)20 8069 5000
Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom
Latest content on this profile
- Article: Creating truly effective communications - the impact of high speed, high octane messaging
- In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.
Research Partnership
- Research Partnership makes two senior appointments to bolster its US and MedTech operations
- Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.
Research Partnership
- Case study: How segmentation of treaters guided a novel product launch in the allergy space
- Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment of Serious Allergic Reactions.
Research Partnership
- Article: War in the Blood - The battle takes shape in the burgeoning European oncology CAR-T market access space
- Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum's Deep Dive.
Research Partnership
- Research Partnership wins prestigious 2023 BOBI Award
- We are delighted to announce Research Partnership were announced the winners in the ‘Creative Fieldwork Team of the Year’ category at the BHBIA’s Best of Business Intelligence (BOBI) Awards.
Research Partnership
- Case study: How we provided in-depth knowledge of electrosurgical generators among target segments and settings in the US market
- Find out how we helped our client to identify clinician roles and responsibilities, pain points and drivers and barriers with respect to a current medical device.
Research Partnership
